Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of October 2017, specifically dated October 17, 2017. The filing serves to announce a significant intellectual property milestone regarding the company's lead drug candidate, Piclidenoson (CF101).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event reported is the issuance of Patent No. 10-1741281 by the Korean Intellectual Property Office. The patent is titled "Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-MECA/CF-101) For Treatment of Psoriasis" and covers the psoriasis indication for Piclidenoson.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" from the attached press release (Exhibit 99.1) into the company's Registration Statements on Form F-3. No specific numerical guidance or detailed risk factors are elaborated within the body of this specific Form 6-K text.
Investor Verification Checklist
- Verify the scope and enforceability of Patent No. 10-1741281 in South Korea.
- Review the full text of the attached press release (Exhibit 99.1) for detailed forward-looking statements.
- Confirm the status of clinical trials for Piclidenoson in the psoriasis indication.
- Check subsequent filings for any updates on regulatory approvals or commercialization plans in Korea.